AZ to terminate 700 US jobs
pharmafile | December 9, 2016 | News story | Manufacturing and Production, Medical Communications | AstraZeneca, job cuts
AstraZeneca has revealed that it plans to cut 700 positions across the US by 10 February 2017, including 120 positions at its US headquarters in Wilmington, Delaware, as part of the company’s growth strategy.
“These changes reflect the ongoing focus to further streamline and drive greater efficiency across the entire organization,” the firm said in a statement. “We continue to face loss of exclusivity impacts from many of our legacy products and work to compete in an ever-changing external environment.”
At its peak, the Delaware site employed 5,000 staff in 2005 following a more than $100 million incentive package from then-Delaware governer Tom Carper in 1999.
Carper himself said of the news: “AstraZeneca’s announcement of layoffs to its Delaware headquarters is deeply disappointing. While this is a tough time for the company, I am hopeful it will gain solid footing and be able to grow and thrive with the new drugs in its pipeline.”
AstraZeneca are not the only company to announce cuts this week as Mylan revealed it is to shave off 10% of its global workforce in a major restructure following the scandal surrounding its severe hiking of its flagship EpiPen auto-injector.
“The remaining impacted roles are field-based roles across the US and include both sales and non-sales roles,” said company spokeswoman Abigail Bozrath. “These changes are specific to the US Commercial Business and do not apply to other parts of the business, including Newark, or other US-based global employees.”
“AstraZeneca is committed to treating every employee with dignity and respect throughout this process. Employees who are impacted will be provided with internal and external assistance and support,” Bozrath added.
Matt Fellows
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
